GlassScriptPhysician profile
Moaath Mustafa Ali
NPI 1356768287
$2,788.21
in general payments reported to CMS, 2019-2025
11 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2021: $119 · 2022: $1,535 · 2024: $21.63 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,410.00 | 2022 | |
| Syndax Pharmaceuticals, INC. | $427.46 | 2025 | Revuforj |
| Janssen Research & Development, LLC | $185.52 | 2025 | |
| Novartis Pharmaceuticals Corporation | $133.64 | 2025 | |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $120.30 | 2019 | |
| Amgen INC. | $118.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $115.61 | 2019 | |
| Janssen Biotech, INC. | $102.40 | 2025 | Tremfya |
| Incyte Corporation | $49.42 | 2024-2025 | Jakafi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moaath Mustafa Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.